<DOC>
	<DOCNO>NCT01838174</DOCNO>
	<brief_summary>We hypothesize novel melanocortin-mediated anti-inflammatory effect Adrenocorticotropic hormone ( ACTH ) reduce axonal loss follow ON limit inflammatory optic nerve injury . We compare effect ACTH intravenous methylprednisolone therapy axonal injury follow ON use ocular coherence tomography ( OCT ) , sensitive , reproducible noninvasive tool measure retinal nerve fiber layer ( RNFL ) thickness . The primary outcome average RNFL thickness 6 month . Additional pre-specified statistical analysis compare difference mean RNFL thickness 6 month affect eye IV methylprednisolone- Acthar-treated group , mean 6-month affect eye RNFL thicknesses adjust baseline unaffected eye RNFL . The secondary outcome measure examine frequency optic nerve RNFL swell IV methylprednisolone- Acthar-treated group 1 3 month . The tertiary outcome change mfVEP amplitude latency , ONHP detection , pupillary diameter ( UTSW ) . A predefined exploratory outcome compare ganglion cell plus inner plexiform layer ( GC+IPL ) thickness 6 month treatment group</brief_summary>
	<brief_title>A Phase IV Trial Neuroprotection With ACTH Acute Optic Neuritis</brief_title>
	<detailed_description>Patients first episode unilateral acute optic neuritis ( ON ) treat either 3 day IV methylprednisolone follow 11 day oral prednisone 15 day intramuscular ( IM ) sub-cutaneous corticotropin ( SQ ) Acthar , adrenocorticotropic hormone ( ACTH ) . This single blind , parallel active group , randomize control trial 60 people clinically unilateral acute optic neuritis ( ≤ 2 week vision loss ; without previous diagnosis relapse remit multiple sclerosis ( MS ) treat either ACTH IV methylprednisolone/prednisone ( IVMP ) 2 week . The primary , secondary , tertiary outcomes note . The assess physician blind treatment minimize bias . We intend recruit target number 3 participant per month complete recruitment within 10 month . This rate recruitment estimate incidence optic neuritis among visit Rocky Mountain MS Center University Texas Southwestern ( tertiary care MS center &gt; 6,000 patient visits/year ) . Participants assess inclusion/exclusion criterion treat neurologist Rocky Mountain MS Center ( PI- Dr. Jeffrey Bennett ) University Texas Southwestern ( PI - Dr. Elliot Frohman ) , follow informed consent , randomize gender , prior diagnosis MS , disease modify treatment ( DMT ) usage ( interferon vs. Glatiramer Acetate vs. Tysabri/Gilenya/Aubagio/Tecfidera vs. treatment ) , time randomization binary minimization data . We expect enroll 30 subject per institution . Following informed consent randomization , participant receive treatment either high dose methylprednisolone ( 1000 mg IV daily 3 day follow 60 mg oral prednisone daily 11 day ) Acthar ( 80 U IM SQ daily 5 day follow 40 U IM SQ daily 10 day ) . Clinical follow-up treating physician plan month 0 , 1 , 3 , 6 . During visit , Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart , low contrast acuity ( 2.5 % ) , color vision ( Farnsworth D-15 ) assess . OCT evaluation ( ONH macular cube ) perform month 0 , 1 , 3 6 month use spectral domain OCT ( Cirrus OCT ; Carl Zeiss Meditec , Dublin , California , USA ) . Automated visual field ( Humphrey 30-2 SITA ) perform baseline month 6 . MfVEP , multifocal electroretinography ( mfERG ) , fundus photography ( assess pallor ) pupillometry perform baseline , month 3 month 6 cohort patient recruit University Texas Southwestern . The patient 's treat neurologist perform blood test magnetic resonance imaging ( MRI ) evaluation exclude cause optic neuropathy initial study visit part routine care . RNFL edema define either average RNFL thickness great 95th percentile age match normal database ratio RNFL thickness ( affected/fellow eye ) great 1.1 quadrant.11 The study sit collect report data adverse event ( AEs ) serious adverse event ( SAEs ) per standard practice . A representative UTSW determine patient randomization accounting variable note . Detailed Patient Schedule Assessments Month 0 , within 2 week onset vision loss ( approximately 7 hour ) : - Consent Discussion Study Expectations - Eligibility Checklist - Review Medical History &amp; Demographics - Record list Con Meds , Comorbidities , Symptoms time Diagnosis - Obtain Randomization Number - Eye Testing ( OCT - [ Optic Disc Cube 200x200 Macular Cube 200x200 ] , VEP , Visual Acuity [ High Contrast ETDRS ] , Low-contrast Letter Acuity [ Sloan 2.5 % 1.25 % letter ] , Color Vision [ Farnsworth D15 ] , mfVEP , mfERG , Humphrey 's visual field ( HVF ) , fundus photography , Pupillometry ) - Administer Study Medication ( either IM SQ Acthar Gel OR IV Methylprednisolone oral taper ) - Labs MRI , per standard care Month 1 , +/- 3 day ( approximately 5 hour ) : - Review AEs Con Meds - Eye Testing ( OCT - [ Optic Disc Cube 200x200 Macular Cube 200x200 ] , VEP ( UTSW ) , Visual Acuity [ High Contrast ETDRS ] , Low-contrast Letter Acuity [ Sloan 2.5 % 1.25 % letter ] , Color Vision [ Farnsworth D15 ] , Humphrey 's visual field ( HVF ) UTSW , fundus photography UTSW ) Month 3 , +/- 3 day ( approximately 5 hour ) : - Review AEs Con Meds - Eye Testing ( OCT - [ Optic Disc Cube 200x200 Macular Cube 200x200 ] , VEP , Visual Acuity [ High Contrast ETDRS ] , Low-contrast Letter Acuity [ Sloan 2.5 % 1.25 % letter ] , Color Vision [ Farnsworth D15 ] , mfVEP , mfERG , Humphrey 's visual field ( HVF ) UTSW , fundus photography ( UTSW ) , Pupillometry UTSW ) Month 6 , +/- 3 day ( approximately 5 hour ) : - Review AEs Con Meds - Eye Testing ( OCT - [ Optic Disc Cube 200x200 Macular Cube 200x200 ] , VEP , Visual Acuity [ High Contrast ETDRS ] , Low-contrast Letter Acuity [ Sloan 2.5 % 1.25 % letter ] , Color Vision [ Farnsworth D15 ] , mfVEP , mfERG , Humphrey 's visual field ( HVF ) , fundus photography , Pupillometry )</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . Male female patient age 18 55 year , inclusive . 3 . Diagnosis clinically unilateral acute demyelinate optic neuritis ( ADON ) 4 . Clinical sign symptom ADON start within 14 day prior intend randomization ( loss vision , pain movement , impairment color vision ) . 5 . The qualify episode optic neuritis must first clinical episode optic neuritis affect eye . 6 . Able undergo treatment intravenous methylprednisolone Acthar gel . 1 . Functionally clinically relevant comorbidity affect eye ( e.g. , glaucoma , amblyopia , optic nerve hypoplasia , macular hole , macular edema , vitreomacular traction , uveitis , diabetes , optic neuritis , diseases optic nerve history thereof ) . 2 . Bilateral optic neuritis . 3 . Concurrent functionally clinically relevant disturbance eye affect ADON . 4 . High clinical likelihood form optic neuritis ADON ( e.g. , pain movement , light perception , severe optic disk edema , atrophic optic disk , retinal exudate , hemorrhage ) . 5 . Nonassessable OCT screening . 6 . Refractive error great ±5 diopter ( presurgical value use patient undergone refractive surgery ) . 7 . Patients immune system disorder MS ADON ( e.g . rheumatoid arthritis , scleroderma , Sjogren 's syndrome , Crohn 's disease , ulcerative colitis , etc . ) know immunodeficiency syndrome ( AIDS , hereditary immune deficiency , druginduced immune deficiency ) . Diagnosis neuromyelitis optica exclude patient study account data analysis . 8 . Prior treatment IV methylprednisolone ( IVMP ) Acthar gel within past 30 day . 9 . Treatment rituximab , mitoxantrone , cyclophosphamide , mycophenolate , azathioprine , alemtuzumab , ocrelizumab , nonapproved agent treatment relapse form MS. 10 . Concurrent use 4aminopyridine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Optic Neuritis</keyword>
</DOC>